The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” . PLYMOUTH MEETING, Pa. ,

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

JANUARY 19, 2024

Currently, several alpha particle emitters are being investigated in clinical trials. When alpha-emitting radionuclides are delivered to cancer cells, the emitted alpha particles cause substantial damage to the DNA of the cells, leading to cell death. Guarnaschelli in the webinar.

DNA 66

DNA Radiology FDA Approval Development 66

pharmaphorum

APRIL 7, 2021

The collaboration will focus on combining Artios’ DNA damage response (DDR) drug candidates with Novartis’ radioligand therapies, which consist of tumour-targeting molecules carrying radioactive isotopes that can deliver a cell-killing dose of radiation to malignant cells. It’s also providing research funding.

DNA 52

DNA Licensing Licensing Gene Therapy 52

Drug Discovery World

APRIL 8, 2024

Bold Therapeutics’ BOLD-100, a ruthenium-based small molecule, acts by targeting GRP78 to modulate the unfolded protein response (UPR) and by generating reactive oxygen species (ROS) leading to DNA damage and cell cycle arrest.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

XTalks

JANUARY 26, 2024

This technology, which allows for precise editing of DNA at specific locations, has been a major focus in the field due to its potential to directly target and modify cancer-causing genes. Clinical trials have demonstrated the potential of CRISPR/Cas9 in this field.

Research 118

Research Gene Editing Gene Genetics 118

Delveinsight

SEPTEMBER 2, 2021

In this case, Delfi is developing a highly sensitive and specific assay intended for comprehensive and cost-effective distribution and adoption by utilizing an advanced machine learning algorithm to the circulating DNA fragment patterns, which can be evaluated through low-cost sequencing.

Marketing 72

Marketing Radiology Drugs Drug Delivery 72